doi:10.19982/j.issn.1000-6621.20220316

Abstract

CLC Number:

Figures/Tables 4

References 16

[1]	林果为, 王吉耀, 葛均波. 实用内科学. 15版. 北京: 人民卫生出版社, 2017: 524-524.
[2]	中华医学会感染病学分会. 隐球菌性脑膜炎诊治专家共识. 中华传染病杂志, 2018, 36 (4): 193-199. doi: 10.3760/cma.j.issn.1000-6680.2018.04.001. doi: 10.3760/cma.j.issn.1000-6680.2018.04.001
[3]	Baluku JB, Musaazi J, Mulwana R, et al. Prevalence and Predictors of CD4⁺ T-Lymphocytopenia Among HIV-Negative Tuberculosis Patients in Uganda. Res Rep Trop Med, 2020, 11: 45-51. doi: 10.2147/RRTM.S252550. doi: 10.2147/RRTM.S252550
[4]	World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021.
[5]	Sharma S, Sharma M, Bose M. Mycobacterium tuberculosis infection of human monocyte-derived macrophages leads to apoptosis of T cells. Immunol Cell Biol, 2009, 87(3): 226-234. doi: 10.1038/icb.2008.97. doi: 10.1038/icb.2008.97 URL
[6]	Macdonald SH, Woodward E, Coleman MM, et al. Networked T cell death following macrophage infection by Mycobacterium tuberculosis. PLoS One, 2012, 7(6): e38488. doi: 10.1371/journal.pone.0038488. doi: 10.1371/journal.pone.0038488
[7]	Chedid C, Kokhreidze E, Tukvadze N, et al. Association of baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered cohort study. Int J Infect Dis, 2020, 100: 199-206. doi: 10.1016/j.ijid.2020.09.017. doi: 10.1016/j.ijid.2020.09.017 pmid: 32920230
[8]	Bowen LN, Smith B, Reich D, et al. HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment. Nat Rev Neurol, 2016, 12(11): 662-674. doi: 10.1038/nrneurol.2016.149. doi: 10.1038/nrneurol.2016.149 pmid: 27786246
[9]	Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis, 2009, 48(7): 856-862. doi: 10.1086/597262. doi: 10.1086/597262 pmid: 19222372
[10]	Hardison SE, Ravi S, Wozniak KL, et al. Pulmonary infection with an interferon-gamma-producing Cryptococcus neoformans strain results in classical macrophage activation and protection. Am J Pathol, 2010, 176(2): 774-785. doi: 10.2353/ajpath.2010.090634. doi: 10.2353/ajpath.2010.090634 pmid: 20056835
[11]	Jarvis JN, Harrison TS, Corbett EL, et al. Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease? AIDS, 2010, 24(4):612-614. doi: 10.1097/QAD.0b013e32833547f7. doi: 10.1097/QAD.0b013e32833547f7 pmid: 19952711
[12]	胡蝶飞, 贾庆雨, 黄力毅. 非HIV相关性隐球菌性脑膜炎的临床特点分析. 广西医科大学学报, 2017, 34(6): 920-921. doi: 10.16190/j.cnki.45-1211/r.2017.06.037. doi: 10.16190/j.cnki.45-1211/r.2017.06.037
[13]	刘巧. 327例结核性脑膜炎与96例隐球菌性脑膜炎临床分析. 成都: 四川大学, 2007. doi: 10.7666/d.y1194439. doi: 10.7666/d.y1194439
[14]	王晓光, 徐启桓. 新型隐球菌性脑膜炎65例临床分析. 中国实用内科杂志, 2004, 24(5): 310. doi: 10.3969/j.issn.1005-2194.2004.05.026. doi: 10.3969/j.issn.1005-2194.2004.05.026
[15]	White A, Liu X, Das SU. Case 4: Weakness and Headaches in a 14-year-old Boy. Pediatr Rev, 2018, 39(8): 424-426. doi: 10.1542/pir.2016-0164. doi: 10.1542/pir.2016-0164 pmid: 30068745
[16]	谢朝云, 李耀福, 蒙桂鸾, 等. 颅骨钻孔侧脑室引流术后颅内感染影响因素分析. 中华医院感染学杂志, 2020, 30(2): 212-215. doi: 10.11816/cn.ni.2020-190197. doi: 10.11816/cn.ni.2020-190197

日期 (年-月-日)	白细胞计数 (×10⁹/L)	淋巴细胞计数 (×10⁹/L)	淋巴细胞百分比(%)
2021-12-08	6.3	0.17	2.7
2021-12-26	8.9	0.29	3.3
2022-01-05	9.9	0.66	6.7
2022-01-26	7.7	0.75	9.8
2022-02-09	7.6	0.64	8.4

日期 (年-月-日)	颅内压 (mmH₂O)	甘露醇用量	Glasgow 评分(分)	白细胞计数 (×10⁶/L)	总蛋白 (g/L)	葡萄糖 (mmol/L)	氯化物 (mmol/L)
2021-12-09	380	25g/次,1次/8h	5	20	3.63	0.02	103.9
2021-12-26	80	-	6	10	0.72	0.09	122.6
2022-01-06	160	20g/次,1次/12h	8	10	0.71	0.85	136.4
2022-01-26	280	20g/次,1次/8h	11	1	0.59	1.21	124.1
2022-02-09	120	20g/次,1次/12h	11	1	0.81	2.31	123.4

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 16

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397.
[2]	Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407.
[3]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[4]	Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424.
[5]	Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431.
[6]	An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438.
[7]	Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443.
[8]	Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453.
[9]	Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459.
[10]	Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470.
[11]	Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476.
[12]	Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481.
[13]	Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497.
[14]	Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504.
[15]	Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512.